EPT Fumarate Research Chemical substituted tryptamine laboratory material from Raw Lab Chems
EPT Fumarate Price range: € 76,00 through € 320,00
Back to products
2-Methyl-AP-237 HCl Powder synthetic opioid chemical research material from Raw Lab Chems
2-METHYL-AP-237 HCl Powder Price range: € 70,00 through € 250,00

2-METHYL-AP-237 HCl Pellets – 20mg

Price range: € 14,00 through € 850,00

2-Methyl-AP-237 HCl Pellets are described as a compressed research preparation containing a synthetic opioid-related compound belonging to the cinnamylpiperazine chemical family.

The active compound is identified in the supplied source as a methyl-substituted structural analogue of bucinnazine (AP-237), presented in hydrochloride salt form.

The source provides a labeled ingredient quantity per pellet, a systematic chemical name, a CAS Registry Number, and molecular identity information.

Scientific research concerning this substance includes forensic chemical identification, comparative structural characterization, and analytical investigation of synthetic opioid derivatives.

However, the stated pellet composition, purity, independent laboratory testing, manufacturing consistency, and Certificate of Analysis availability have not been independently substantiated.

The finished pellets are not established as certified reference materials or validated quantitative calibration standards.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-P-13087 Category:
Description

2-Methyl-AP-237 HCl Pellets 20mg – Synthetic Opioid Research Material

Product Overview

2-Methyl-AP-237 HCl Pellets are described in the supplied information as compressed research units containing a synthetic opioid-related compound in hydrochloride salt form.

The named compound belongs to the cinnamylpiperazine family and is structurally related to bucinnazine, also known as AP-237.

Its designation reflects a methyl-substituted derivative of the parent chemical framework.

The supplied material is associated with forensic chemical identification, structural comparison, and laboratory analytical research involving synthetic opioid analogues.

The source identifies a specific labeled ingredient quantity per finished pellet.

However, no batch-specific quantitative assay or finished-unit content-uniformity report accompanied the information.

The stated ingredient quantity therefore remains a source-provided label claim rather than an independently verified measurement.

The source also describes high ingredient purity, third-party testing, and controlled manufacturing procedures.

No actual independent analytical certificate or supporting manufacturing documentation was provided.

The finished preparation is not established as a certified reference material, validated quantitative calibrator, or approved pharmaceutical product.

Chemical Identity & Classification

The supplied source identifies the active compound as a member of the cinnamylpiperazine family.

The following identifiers are reproduced from the source:

  • Common name: 2-Methyl-AP-237 hydrochloride
  • Chemical classification: Synthetic opioid; cinnamylpiperazine derivative
  • Structural relationship: Methyl-substituted analogue of bucinnazine
  • Reported systematic name: 1-[2-Methyl-4-[(2E)-3-phenylprop-2-en-1-yl]piperazin-1-yl]butan-1-one hydrochloride
  • Reported CAS Registry Number: 98608-59-4
  • Reported molecular formula: C18H26N2O · HCl
  • Reported molecular weight: 322.87 g/mol
  • Reported presentation: Compressed pellets

The supplied molecular formula and molecular weight are approximately consistent.

However, arithmetic consistency does not independently confirm the identity of the compound present in the actual pellets.

The hydrochloride designation is relevant because the salt form must be distinguished from the corresponding free-base compound.  2-Methyl-AP-237 HCl Pellets

The source does not provide a verified chemical structure report, finished-pellet excipient specification, or independently confirmed ingredient assay.

Researchers may consult PubChem for public chemical-reference information, taking care to distinguish the hydrochloride salt from the corresponding free-base structure.

Chemical & Physical Characteristics

The supplied source describes the product as compressed pellets.

No actual product-specific inspection report, pellet-dimension specification, total unit mass, or excipient list was provided.

The physical presentation therefore remains a source-provided description.

The named active compound is described as a substituted cinnamylpiperazine derivative.

Its proposed molecular framework includes a piperazine ring associated with a cinnamyl-containing group and an additional methyl substitution.

These structural characteristics distinguish it from several other synthetic opioid families.

However, structural classification alone does not establish the finished product’s purity, physical properties, stability, or toxicological characteristics.

The source does not provide experimentally verified melting-point data, solubility measurements, degradation profiles, or finished-formulation stability studies.

The source also does not identify the additional ingredients that may be present in the compressed preparation.

The reported chemical formula and molecular weight describe the named active compound rather than the complete pellet formulation.

The source recommends cool, dry storage protected from light.

No validated product-specific shelf-life or stability report accompanied that recommendation.

Purity & Analytical Verification

The supplied source claims ingredient purity of at least 98%, with independent laboratory verification.

However, no actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, or third-party laboratory report was provided.

Accordingly, the stated purity threshold is not independently confirmed.

For a compressed preparation, the purity of the named ingredient and its actual quantity within a finished pellet are separate analytical characteristics.

A purity claim does not independently establish finished-unit composition or content uniformity.

The source identifies HPLC, GC-MS, LC-MS, and NMR spectroscopy as analytical techniques relevant to the named compound.

These techniques may provide information concerning chemical identity, structural characteristics, impurity profiles, and analytical specificity.

However, mentioning an analytical technique does not establish that it was performed on the actual product.

The source also describes the pellets as suitable for reference-standard applications.

That description does not establish certified reference-material status or validated quantitative calibration performance.

No assigned reference values, uncertainty statements, metrological traceability records, or independently verified finished-unit specifications were supplied.

Quality Control & Batch Integrity

The supplied source claims independent laboratory testing, batch-specific traceability, and ISO-compliant production.

It also states that Certificates of Analysis may be available upon request.

No actual certificate, accreditation record, manufacturing audit, independent testing report, or finished-unit quality-control document accompanied these claims.

They therefore remain unverified supplier statements.  2-Methyl-AP-237 HCl Pellets

For reproducible scientific documentation, relevant records may include the verified chemical identifier, batch number, analytical findings, receipt date, and available storage history.

For a compressed pellet preparation, the identity and purity of the named active compound should be distinguished from the composition and consistency of the finished units.

The supplied information does not establish independently verified pellet content uniformity, excipient composition, or quantitative accuracy of the labeled ingredient amount.

The claim of ISO-compliant production is also insufficient to establish certification or accreditation.

No applicable standard number, certification body, scope, or supporting audit documentation was provided.

Safety, Handling & Laboratory Precautions

2-Methyl-AP-237 belongs to a synthetic opioid-related chemical family associated with potentially serious toxicological hazards.

Synthetic opioids may present risks including profound central nervous system depression and life-threatening respiratory depression following exposure.

Laboratory personnel should follow institutional hazardous-chemical procedures and consult available chemical-safety documentation.

Relevant controls include restricted access, protective equipment, contamination prevention, accidental-exposure procedures, and appropriate chemical-waste management.

The compressed presentation does not establish safety for human or veterinary exposure.

The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.

Because the actual finished-unit composition and purity have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements.

Any accidental exposure should be managed under institutional emergency procedures.

Packaging, Labeling & Storage

The supplied source describes protective packaging, appropriate chemical labeling, and professional shipment arrangements.

However, no actual packaging specification, container-validation report, or shipment-condition record was supplied.

The source recommends cool, dry, light-protected storage and suggests a temperature range of 2–8°C for longer-term preservation.  2-Methyl-AP-237 HCl Pellets

No validated product-specific stability data was provided to establish that this temperature range is necessary or sufficient for a particular shelf life.

Inventory records should preserve the product designation, hydrochloride salt form, any available batch identifier, and relevant storage observations.

The labeled ingredient quantity should be recorded as a source-provided specification unless independently verified.

Storage and containment requirements should be determined through institutional risk assessment and available chemical-safety documentation.

Intended Research Use & Market Positioning

The supplied scientific context places 2-Methyl-AP-237 within forensic chemical identification and analytical research involving synthetic opioid derivatives.

Its structural relationship to bucinnazine provides context for comparative chemical classification.

The source references chromatographic identification, mass-spectrometric characterization, and investigation of cinnamylpiperazine compounds.

These references describe laboratory research topics rather than evidence of validated performance for the actual finished pellets.

The supplied Raw Lab Chems catalog includes 2-Methyl-AP-237 HCl Pellets and a separate 2-Methyl-AP-237 HCl Powder listing.

These are differently presented products, and the supplied information does not establish equivalent chemical purity, batch identity, or formulation characteristics.

A further catalog entry identifies O-DSMT Pellets, which refers to a different opioid-related compound and should not be considered chemically interchangeable.

These references provide catalog context rather than evidence of certified reference-material status or product equivalence.

Ordering, Availability & Fulfillment

The supplied source describes protective packaging, shipment tracking, and international laboratory distribution.

No current inventory record, shipment authorization, carrier documentation, or verified delivery information was supplied.

Consequently, no availability, delivery, customs-clearance, or transportation-compliance guarantee is asserted.

Synthetic opioid compounds may be subject to controlled-substance, analogue, pharmaceutical, or other chemical regulations.

Institutional acquisition, possession, transportation, importation, and exportation must be assessed under applicable laws.

Research-only labeling does not establish a legal exemption.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.  2-Methyl-AP-237 HCl Pellets

2-Methyl-AP-237 is a synthetic opioid-related compound whose possession, acquisition, transfer, transportation, importation, exportation, and laboratory investigation may be restricted or prohibited depending on the jurisdiction.

The supplied information does not establish universal legal status or regulatory authorization.

Institutions remain responsible for determining the applicable legal requirements and obtaining any necessary permissions.

No medical approval, consumer-use authorization, or regulatory exemption is implied by this description.

Additional information
Quantity (pellets)

5

,

10

,

25

,

50

,

100

,

250

,

500

,

1000

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “2-METHYL-AP-237 HCl Pellets – 20mg”
Shipping & Delivery